Optimizing the Management of Melanoma: Future Directions in Care
Closing out his discussion on the management of metastatic melanoma, expert oncologist Sajeve Thomas, MD, summarizes unmet needs and looks toward future evolutions in the treatment paradigm.
Adverse Event Management: Improving Use of IO Therapy in Metastatic Melanoma
Comprehensive insight from an expert oncologist regarding the adverse event profile of immunotherapy (IO) agents and how these can be mitigated while treating patients with metastatic melanoma.
Disease Progression After 1L Therapy and Selection of 2L Therapy in Metastatic Melanoma
Following his review of first-line treatment options in the setting of metastatic melanoma, Sajeve Thomas, MD, considers how he would manage patients at disease progression.
Factors in Selecting First-Line Therapy for Patients With Metastatic Melanoma
Expert perspective on the optimal selection and use of first-line therapy in patients diagnosed with metastatic melanoma in the context of the current treatment paradigm.
LAG-3/PD-1 Inhibitor Therapy in Unresectable or Metastatic Melanoma: The RELATIVITY-047 Trial
Sajeve Thomas, MD, reflects on the RELATIVITY-047 trial combining relatlimab, a LAG-3 inhibitor, with nivolumab, a PD-1 inhibitor, in the first-line setting of unresectable or metastatic melanoma.
First-Line Treatment Armamentarium for Patients With Unresectable or Metastatic Melanoma
A comprehensive review of how the first-line treatment armamentarium in unresectable or metastatic melanoma has evolved over time.
A 63-Year-Old Man With Metastatic Melanoma and Typical Workup Strategies at Diagnosis
Expert oncologist Sajeve Thomas, MD, reviews the diagnosis and first-line management of a patient who presents with metastatic melanoma.
2 Commerce Drive Cranbury, NJ 08512